BioSpace

BioSpace stands out as the top online hub for life science professionals, offering the latest industry news and career opportunities. With a rich history spanning more than 30 years, BioSpace has been dedicated to connecting talented individuals with job openings in the biotechnology and pharmaceutical sectors. Moreover, it has fostered better communication and collaboration among leaders in the biopharmaceutical field, enhancing discovery and innovation.

National

English

Online/Digital

Outlet metrics

Domain Authority

Ranking

Global

#70282

United States

#18685

Science and Education/Biology

#22

Traffic sources

Monthly visitors

Articles

Unusual New Fund Launches to Unlock Some $30B of Capital ‘Trapped’ in Public Biotechs

6 days ago | biospace.com | Annalee Armstrong

Taking a page out of the private equity playbook, a new fund has emerged to recycle over $30 billion of capital “trapped” in failed public biotechs. London-based Alis Biosciences launched on Friday with a pledge to return to shareholders capital that’s invested in publicly listed companies that have suffered a clinical failure or other stumbling block, with nowhere to turn. The plan—which is carefully laid out in three different structures—is a familiar tactic in the private equity world.
Here Today, Gone Tomorrow: Trump’s Policies Give Biopharma Whiplash

6 days ago | biospace.com | Jef Akst |Heather McKenzie |Annalee Armstrong

The uncertainty that came with Donald Trump’s electoral victory in November has only compounded now that he’s in office. Similar question marks have surrounded Robert F. Kennedy Jr., whose anti-vaccine rhetoric and overall criticism of agencies within the Department of Health and Human Services he now heads were potential concerns for the biopharma industry from the first rumors that he’d be Trump’s nominee for HHS secretary.
Biotech’s Next Phase Will Be All-American: Pitchbook

1 week ago | biospace.com | Annalee Armstrong

After the COVID-19 pandemic and a two-year market correction, biotech’s next era will be all about America-first to match protectionist trade policies and other policy shifts to accelerate homegrown manufacturing, Pitchbook said in a new report.
Sanofi Bets More Than $1.8 Billion in Biobucks on AI-Developed Bispecifics

1 week ago | biospace.com | Dan Samorodnitsky

Sanofi continues to plant its artificial intelligence roots, signing a licensing deal potentially worth more than $1.8 billion with Earendil Labs for two bispecific antibodies. Earendil, a Delaware-based AI research and development company focused on biologics, will get a $125 million upfront payment from Sanofi. Down-the-road development and commercial milestones could add as much as $1.72 billion, plus tiered royalties on sales. The antibodies are called HXN-1002 and HXN-1003.
Kennedy’s Hunt for a Connection Between Vaccines and Autism Is a Sham

1 week ago | biospace.com | Dan Samorodnitsky

Last week, Health and Human Services Secretary Robert F. Kennedy Jr. announced that he is marshaling the force of his agency to discover the link between vaccines and autism. He suggested that this new research project could be completed by September, a lightning quick turn-around for any research project. He offered no other details on what exactly he and HHS will do. Of course he does not need to wait even as long as September.
Former FDA Officials Sound Alarm: Visible Changes May Be “Tip of the Iceberg”

1 week ago | biospace.com | Heather McKenzie

As the FDA faces an uncertain future following massive workforce cuts enacted by Health and Human Services Secretary Robert F. Kennedy Jr., two former agency officials are speaking out, expressing concern over potential drug review delays while also seeking to reassure anxious stakeholders about the state of the FDA.
Bluebird’s Second Suitor, Ayrmid, Fails To Produce an Offer

1 week ago | biospace.com | Dan Samorodnitsky

Despite weeks of communication between the two companies, bluebird bio announced Wednesday that Ayrmid has not submitted a binding proposal to buy the company, despite an unsolicited offer in late March. Bluebird had already entered into a purchase agreement with the investment firms Carlyle and SK Capital Partners in February for $3 per share, or $30 million total.
Glycomine Gets $115M Series C for Rare Disease, Aims for Phase II Launch Mid-Year

1 week ago | biospace.com | Dan Samorodnitsky

California-based biopharma Glycomine announced a $115 million Series C raise Wednesday to push its lead rare disease molecule into Phase IIb trials. “We’re working on glycosylation disorders, putting sugar chains on proteins. There are hundreds of those,” CEO Steve Axon told BioSpace in an interview.
Tariff Turmoil, FDA’s Future, Pfizer’s Obesity Setback and CEO Salaries Revealed

1 week ago | biospace.com | Heather McKenzie |Jef Akst |Annalee Armstrong |Dan Samorodnitsky

> Listen on Spotify> Listen on Apple Products> Listen on Amazon Music> Listen on iHeartIt’s all about tariffs again this week. No sooner had Donald Trump announced that “major” tariffs on the pharmaceutical industry would be coming “very shortly”—sending stocks spiraling—the president announced a 90-day pause on most taxes for imports from countries not named China. But this respite was not to last.
J&J Sets Tariff Tone as Q1 Earnings Begin To Roll In

1 week ago | biospace.com | Annalee Armstrong

Johnson & Johnson kicked off the first quarter earnings period on Tuesday, sending a slight sigh of relief across the industry. That’s because the company only reported modest impacts from the ongoing tariff uncertainty, which analysts have predicted will be the elephant in the room on the industry’s calls this quarter. Indeed, although J&J executives spoke for 37 minutes before addressing tariffs, it was the first question out of the gate when the call pivoted to Q&A.